

Quantifying antibody dynamics of severe and non-severe patients with COVID-19

Fernanda Ordoñez-Jiménez^{a,**}, Rodolfo Blanco-Rodríguez^{a,**}, Alexis Erich S. Almocera^b, Gustavo Chinney-Herrera^a and Esteban Hernández-Vargas^{a,c,*}

^a Instituto de Matemáticas, Universidad Nacional Autónoma de México, Boulevard Juriquilla 3001, Querétaro, Qro., 76230, México

^b Division of Physical Sciences and Mathematics, College of Arts and Sciences, University of the Philippines Visayas, Philippines

^c Frankfurt Institute for Advanced Studies, Frankfurt am Main, Germany

ARTICLE INFO

Keywords:

Topological Data Analysis
Immune Responses
Mathematical Modeling
SARS-CoV-2
COVID-19

ABSTRACT

COVID-19 pandemic is a major public health threat with unanswered questions regarding the role of the immune system in the severity level of the disease. In this paper, based on antibody kinetic data of patients with different disease severity, topological data analysis highlights clear differences in the shape of antibody dynamics between three groups of patients, which were non-severe, severe, and one intermediate case of severity. Subsequently, different mathematical models were developed to quantify the dynamics between the different severity groups. The best model was the one with the lowest media value of Akaike Information Criterion for all groups of patients. Although it has been reported high IgG level in severe patients, our findings suggest that IgG antibodies in severe patients may be less effective than non-severe patients due to early B cell production and early activation of the seroconversion process from IgM to IgG antibody.

1. INTRODUCTION

Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the causative agent of one of the largest pandemic in history. COVID-19 pandemic has resulted in about 5 million of deaths and more than 365 million of infected people. Previous coronavirus outbreaks SARS-CoV (2003) and MERS-CoV (2012) showed similar qualitative and quantitative clinical aspects to SARS-CoV-2. In particular, patients with MERS-CoV [29] had viral levels peak in the second week with a median value of 7.21 (log₁₀ copies/mL) in the severe patient group, and approximately 5.54 (log₁₀ copies/mL) in the mild group. On the other hand, in patients with SARS were reported that the virus peaked at 5.7 (log₁₀ copies/mL) between 7 to 10 days after onset of symptoms (dps) [33].

Several multifactorial and complex mechanisms are implicated during the course of COVID-19, which consequently lead to the nature of pathogenesis. COVID-19 patients can be classified into mild, moderate, severe, and critical cases. In patients with SARS-CoV-2 the viral peak was approximately 8.85 (log₁₀ copies/mL) around 5 dps [49], and viral load persisted for 12 days after onset [20]. Severe disease cases reported a mean viral load on admission 60 times higher than the mean of mild disease cases [20]. Remarkably, prolonged viral shedding was presented in severe patients than that of non-severe patients [45].

**First author

*Corresponding author: esteban@im.unam.mx
ORCID(s):




Figure 1: Immune responses associated for the poor clinical outcome in severe COVID-19 patients.

37 The immune system has been pointed out by the scientific community as a key factor between severe and non-
38 severe patients Figure1. Among the immune cells recruited to tackle SARS-CoV-2 in the lungs are virus-specific T
39 cells *e.g.* CD4+ T and CD8+ T cells. The study by Oja *et al.* [30] highlighted that B and T cell responses of critical
40 patients are imbalanced, exhibiting high titers and low virus-specific CD4+ T cell responses. Interestingly, the CD4+
41 T cell response was impaired as well as the functionality [30], that is SARS-CoV-2-specific CD4+ T cells showed
42 decreased production of Interferon- γ (IFN- γ), Interleukin 4 (IL-4) and Interleukin 21 (IL-21). While other studies
43 [47] has shown high levels IL-2, IL-10 and IL-6, COVID-19 patients are less inflamed than influenza patients [25].

44 B cell responses could be indicative of a deregulated immune response in severe COVID-19 patients. Timing is
45 central as the ratio between viral loads and antibody titers during the early phase of disease may be predictive for
46 disease severity [30]. Prospective cohort studies with COVID-19 patients highlight that immunoglobulin M (IgM)
47 started on day 7 and peaked on day 28, while that of immunoglobulin G (IgG) was on day 10 and day 49 after illness
48 onset [45, 30]. Strikingly, these studies revealed that IgG antibody are significantly higher in severe patients than
49 non-severe patients [45].

50 Dissecting the contributions of the identified players in antibody dynamics to severe and non-severe patients with
51 COVID-19 is crucial to develop prophylactic and therapeutic strategies. In this regard, it is important to understand the
52 relationship between data taken from experimental samples of patients with COVID-19 and the severity of the disease.

53 Topological Data Analysis (TDA) is a set of tools based on algebraic topology and whose objective is to retrieve
54 information from high-dimensional databases which are complex to study with traditional statistical methods. The
55 particular tool we used from TDA is the Mapper algorithm. The algorithm was proposed by Singh *et al.* [41] and has

56 since gained relevance in recent years as it offers graphs with clear interpretations that represent a general map of the
57 phenomenon being studied, simplifying and preserving important features of the data. This algorithm has proven its
58 usefulness in various situations such as the study of breast cancer data [28] or image processing [38].

59 On the other hand, mathematical modeling has made valuable contributions to our quantitative understanding of
60 different viral infection such as for Influenza [4, 24, 42, 32, 14, 8, 17], HIV [39, 34, 15, 35], Hepatitis[37, 13], Ebola
61 [26, 27], among many others. For COVID-19, there are a few models at within-host level to quantify SARS-CoV-2
62 dynamics in the host [9, 10, 11, 12, 16, 1, 2, 5]. However, untangling the contributions of different mechanisms by which
63 changes in the immune response in non-severe and severe patients in a temporal manner has not been proposed until
64 now. Therefore, by combining the results of different data sets, topological data analysis and mathematical modelling
65 approaches, the present study aims at clarifying the relative contributions of antibodies between severe and non-severe
66 COVID-19 patients.

67 2. RESULTS

68 **Topological data analysis.** We decided to explore the data using the mapper algorithm for topological analysis of the
69 data in order to find a distinction between severe and non-severe cases that the usual statistical tools fail to recover.
70 The mapper algorithm is a method of replacing a topological space by a simpler one, which captures topological and
71 geometric features of the original space. In the graph resulting from the mapper, the nodes represent the group of data
72 that the algorithm considered similar while the edges between two of them mean that they have non-empty intersection.
73 The size of the nodes is proportional to the number of elements it contains.

74 First we use the data from 262 patients with a single sample per patient, this means that we have a set of 262 points
75 in \mathbb{R}^4 where the entries correspond to the days after onset of symptoms, IgG antibody level, IgM antibody level and
76 the severity with 0 indicating a non-severe case and 1 a severe case. In Figure 2 shows the resulting graph colored
77 according to the severity of the patients described by the data set. The algorithm distinguishes three main groups,
78 labeled A, B and C. In group A the nodes have at least 70% of severe patients, in group B the nodes have between 20%
79 and 60% and in group C there are no severe patients.

80 In order to study these distinctions, we show the violin plots in Figure 3. We first compared the IgG and IgM
81 antibody levels of the data from node groups A, B, and C; and then comparing groups $A \cup B$ and C separated by week.
82 In the violin plots presented on the left of Figure 3 we observe that group B has clearly higher and less dispersed IgG
83 antibody levels than the other groups. As for IgM in group A, it is generally higher than in the other groups. This may
84 indicate a difference between severe cases, however it is insufficient with this information. The following two graphs
85 compares IgG and IgM antibody levels between groups $A \cup B$ and C per week. The $A \cup B$ group represents mostly
86 severe patients. The first three weeks the group $A \cup B$ IgG antibody levels are higher than group C. As for IgM the




Figure 2: Graph generated with the mapper algorithm using 262 samples with the nodes colored by severity percentage. The algorithm distinguishes three main groups, in group A the nodes have at least 70% of samples of severe patients, in group B the nodes have between 20% and 60% and in group C there are no severe patients.




Figure 3: Violin plots comparing IgG and IgM antibody levels for each group A, B and C distinguished from the previous graph. The graph on the left compares IgG and IgM antibody levels between groups A, B and C. The following two graphs compares IgG and IgM antibody levels between groups A ∪ B and C per week. Dashed lines are the median of the data and dotted lines indicate the interquartile range.

87 diagrams are inconclusive. From the above we can conclude that high IgG antibody levels in the first weeks may be
 88 an indicator of a tendency towards a more severe disease state.

89 Of the 262 patients considered in the previous analysis, longitudinal samples were obtained from 41 of them. For
 90 the most part, samples were taken at three-day intervals. In this dataset the ID of each patient was also considered so
 91 that the mapper algorithm recognizes the samples coming from the same person, so the points are in \mathbb{R}^5 . In Figure 4
 92 shows the resulting graph colored according to the severity of the patients, the tail (group F) containing nodes with a
 93 large number of samples followed by a circular shape (group G) that ends with two distinct protrusions (group D and
 94 E). The group E contains the samples with high IgG antibody values, although there are some nodes with medium
 95 levels near the circle. In this same area, nodes with high levels of IgM antibodies are found. In group D, all nodes




Figure 4: Graph generated with the Mapper algorithm using 41 longitudinal samples with the nodes colored by severity percentage. We can observe four main groups, in group D all nodes contain samples of severe patients, while in group E the percentage of severity varies between 0% and 90%. in groups F and G there are no samples of severe patients, however they differ with respect to the number of elements.

96 contain samples of severe patients, while in group E the percentage of severity varies between 0% and 90%. On the
 97 other hand, in groups F and G there are no samples of severe patients, however they differ with respect to the number
 98 of elements and the form in which they are presented. In group F all nodes have at least 12 elements (except for a
 99 single node) and those in group G have at most 11.

100 2.1. Mathematical models

101 The complexity and, at times, redundancy of immune responses to infections often result in arduous and expensive
 102 experimental settings when attempting to identify the key components and their temporal contributions. To dissect
 103 the dynamics observed in patients with COVID-19, mathematical modelling was employed not only as a quantitative
 104 recapitulation of experimental data but as a tool to support or reject less favourable hypotheses on the basis of various
 105 mathematical models as “thought experiments” using the Akaike Information Criterion (AIC) for the model selection
 106 process. We considered six different models. We will now describe three models that seem relevant to us; models 2,
 107 4 and 5 are presented in the Supplementary Material.

108 **Model 1:** This model represents the viral dynamics of SARS-CoV-2 (V) and the dynamics of the T cell (T), B cell
 109 (B), IgM (M) and IgG (G) antibody response. The model is given by:

$$\frac{dV}{dt} = pV - c_T VT - c_M MV - c_G GV - cV, \quad (1)$$

$$\frac{dT}{dt} = r_T V - \delta_T T, \quad (2)$$

$$\frac{dB}{dt} = r_B V - \delta_B B, \quad (3)$$

$$\frac{dM}{dt} = r_M B - \delta_M M, \quad (4)$$

$$\frac{dG}{dt} = r_G B - \delta_G G, \quad (5)$$

110 where p is the rate of viral replication, the terms $c_T VT$, $c_M MV$ and $c_G GV$ are the clearance rate of the virus by the
 111 immune response T cells, IgM and IgG respectively. Clearance rate of the virus is c . Previous modelling work has
 112 suggested using half of the detection levels (less than 50 copies/ml) as initial viral concentration $V(0)$; however, for
 113 patients with COVID-19, $V(0)$ has been estimated approximately in 0.31 copies/ml using a regression model [16]. The
 114 proliferation rates of T cell and B cell are r_T and r_B respectively and are mediated by the viral load. The proliferation
 115 rate of IgM and IgG antibody are r_M and r_G respectively, and are mediated by the level of B cell. δ_T , δ_B , δ_M and δ_G
 116 are the half life of T cell, B cell, IgM antibody and IgG antibody, respectively. The initial levels of T cell, B cell, IgM
 117 antibody and IgG antibody were set to 10^6 , 10, 0.1 and 0.1, respectively.

118 **Model 3:** In this model we considered the viral replication rate modelled by a logistic function with a replication
 119 rate p and a maximum carrying capacity K_V ; this is the maximum viral load. The model is given by:

$$\frac{dV}{dt} = pV \left(1 - \frac{V}{K_V} \right) - c_T VT - c_M MV - c_G GV - cV, \quad (6)$$

$$\frac{dT}{dt} = r_T T \left(\frac{V^m}{V^m + K_T^m} \right) + \delta_T (T(0) - T), \quad (7)$$

$$\frac{dB}{dt} = \frac{r_B V - B}{\tau_b}, \quad (8)$$

$$\frac{dM}{dt} = r_M B - (q + \delta_M) M, \quad (9)$$

$$\frac{dG}{dt} = qM + r_G B - \delta_G G. \quad (10)$$

120 Equation (7) refers to the T cells response against SARS-CoV-2. T cells proliferate at a rate r_T and it is assumed
 121 that the activation of T cell proliferation by V follows a log-sigmoidal form with a half saturation constant K_T . The
 122 coefficient m relates to the width of the sigmoidal function, different values of m were tested, $m = 2$ rendered a better
 123 fit [16]. $T(0)$ is the initial T cells concentration, this represents the T cell homeostasis and it was set to 10^6 .

124 Equation (8) represent the B cells production, which activates the immunoglobulins response against the virus.
 125 This dynamic is modelled by the proliferation of the cells at a rate r_B minus the B cells already produce since these
 126 cells are directly involved in the immunoglobulins proliferation. The parameter τ_b correspond to the activation delay
 127 of the cells production.

128 Equation (9) refers to the IgM dynamic. The model infers that the production of antibodies is not simultaneous but
 129 independent, because IgM is considered a temporary antibody, in contrast to IgG, which shows prolonged immunity,
 130 and that the seroconversion process suggests the early production of IgM for its later conversion to IgG. This serocon-




Figure 5: Schematic representation of the Model 6 proposed. Virus (V) are replicated at a rate of p and inhibited by T cells (T), B cells (B) and antibodies IgM (M) and IgG (G). V induces B and T proliferation. On the other hand, B induces M and G proliferation, while that seroconversion process regulates G proliferation due to M . Positive regulations between processes are highlighted with solid arrows, while negative regulations are marked with dotted arrows.

131 version process is represented by q . The dynamic of IgG antibody proliferation is represent in Eq. (10), where q is the
 132 growth rate associated with seroconversion.

133 **Model 6:** The dynamic of IgG antibody proliferation is modified. Here, the process in which seroconversion
 134 regulates the proliferation of IgG is modeled with a logistic function, where r_q is the growth rate associated with
 135 seroconversion and K_q is the maximum capacity of this process. Figure 5 shows the complexity of the process described
 136 by the following model:

$$\frac{dV}{dt} = pV \left(1 - \frac{V}{K_V} \right) - c_T VT - c_M MV - c_G GV - cV, \quad (11)$$

$$\frac{dT}{dt} = r_T T \left(\frac{V^m}{V^m + K_T^m} \right) + \delta_T (T(0) - T), \quad (12)$$

$$\frac{dB}{dt} = \frac{r_B V - B}{\tau_b}, \quad (13)$$

$$\frac{dM}{dt} = r_M B - (q + \delta_M) M, \quad (14)$$

$$\frac{dG}{dt} = r_q M \left(1 - \frac{M}{K_q} \right) + r_G B - \delta_G G. \quad (15)$$

137 2.2. Stability analysis

138 In this section we perform a sensitivity analysis of Model 6, since it was the one with the best AIC score. To begin
139 with, Eqs. (11)-(15) can be transformed into the following dimensionless form:

$$x' = x(1-x) - \overline{c}_T xy - \overline{c}_M w_M x - \overline{c}_G w_G x - \overline{c}x, \quad (16)$$

$$y' = \overline{r}_T y \mathcal{H}(x, \overline{K}_T) - \overline{\delta}_T (1-y), \quad (17)$$

$$z' = (\overline{\tau}_B)^{-1} (x-z), \quad (18)$$

$$w'_M = \overline{r}_M z - (\overline{q} + \overline{\delta}_M) w_M, \quad (19)$$

$$w'_G = \overline{r}_q w_M (1-w_M) + \overline{\delta}_G (z-w_G), \quad (20)$$

where the function \mathcal{H} is defined by $\mathcal{H}(x, a) = x^m / (x^m + a^m)$ with $m \geq 2$, and the derivatives are with respect to dimensionless time $\tau = pt$. And the overline symbols are the dimensionless parameter that can be obtained by substituting in Eqs. (11)-(15) the variables defined by:

$$\begin{aligned} x &= \frac{V}{K_V}, & y &= \frac{T}{T(0)}, & z &= \frac{B}{r_B K_V}, \\ w_M &= \frac{M}{K_q}, & w_G &= G \cdot \left(\frac{\delta_G}{r_B r_G K_V} \right). \end{aligned}$$

140 For convenience, we call an equilibrium point with viral load x *virus-free* when $x = 0$ and *virus-positive* when
141 $x > 0$. We will only consider equilibrium points with non-negative coordinates. Basic computation yields exactly one
142 virus-free equilibrium which is $E_0 := (0, 1, 0, 0, 0)$.

Let $J(p)$ denote the following Jacobian matrix:

$$\begin{bmatrix} J_{11}(p) & -\overline{c}_T x & 0 & -\overline{c}_M x & -\overline{c}_G x \\ \overline{r}_T y \mathcal{H}_x(x, \overline{K}_T) & \overline{r}_T \mathcal{H}(x, \overline{K}_T) - \overline{\delta}_T & 0 & 0 & 0 \\ (\overline{\tau}_B)^{-1} & 0 & -(\overline{\tau}_B)^{-1} & 0 & 0 \\ 0 & 0 & \overline{r}_M & -(\overline{q} + \overline{\delta}_M) & 0 \\ 0 & 0 & \overline{\delta}_G & \overline{r}_q (1 - 2w_M) & -\overline{\delta}_G \end{bmatrix}$$

where $\mathcal{H}_x = \partial \mathcal{H} / \partial x$ and

$$J_{11}(p) = 1 - 2x - \overline{c}_T y - \overline{c}_G w_G - \overline{c}_M w_M - \overline{c}. \quad (21)$$

Theorem 1. *Let*

$$\lambda = J_{11}(E_0) = 1 - \overline{c_T} - \overline{c}. \quad (22)$$

143 *Then E_0 is asymptotically stable for $\lambda < 0$ and non-hyperbolic for $\lambda = 0$. If $\lambda > 0$, then E_0 is an unstable saddle with*
144 *a four-dimensional stable manifold and a one-dimensional unstable manifold.*

Proof. Evaluating the Jacobian matrix at E_0 yields

$$J(E_0) = \begin{bmatrix} \lambda & 0 & 0 & 0 & 0 \\ 0 & -\overline{\delta_T} & 0 & 0 & 0 \\ (\overline{\tau_B})^{-1} & 0 & -(\overline{\tau_B})^{-1} & 0 & 0 \\ 0 & 0 & \overline{r_M} & -(\overline{q} + \overline{\delta_M}) & 0 \\ 0 & 0 & \overline{\delta_G} & \overline{r_q} & -\overline{\delta_G} \end{bmatrix},$$

145 which implies that E_0 is asymptotically stable for $\lambda < 0$ and is non-hyperbolic for $\lambda = 0$. If $\lambda > 0$, then $J(E_0)$ has
146 exactly one positive eigenvalue λ and four negative eigenvalues. Hence by the Stable Manifold Theorem, E_0 is an
147 unstable saddle with a four-dimensional stable manifold and a one-dimensional unstable manifold. \square

148 *Remark.* In the case where E_0 becomes a saddle for $\lambda > 0$, the solutions $\phi_1(x)$ such that $\phi_1(x) \rightarrow E_0$ at $t \rightarrow \infty$ form
149 a four-dimensional invariant manifold, called the stable manifold of E_0 .

150 Our dimensionless model, Eqs. (16) to (20), admits virus-positive equilibrium points only if $\lambda > 0$. This point with
151 viruses is more complicated to obtain. In the Supplementary Material we present an analysis of the different scenarios
152 in which this equilibrium point can occur.

153 **2.3. Numerical simulations**

154 In order to study the antibody response during the course of SARS-CoV-2 infection, we fixed the parameters related
155 to the dynamics of the virus and T cell with values obtained from [16] and [23]. We estimated the parameters related
156 to the dynamics of the B cells and antibodies IgM and IgG. To estimate these parameters we selected 39 patients who
157 presented a significant temporal change of IgG antibody data and fit our models to that data; of these 39 patients, 3
158 were severe cases found in group D, 4 were severe cases from group E, and 32 were non-severe cases belonging to
159 groups F and G, identified by the topological analysis presented above (Figure 4). The fixed parameters are displayed
160 in Table 1, and they are taken the same for all cases.

161 Parameter optimization was carried out with data from each of the 39 patients considered. The six models were
162 fitted to the data of the 39 patients, and we calculated the AIC score for each patient from Eq. (24). The results showed

Table 1
Model Parameters.

Parameter	Value
p	6.11 [16]
K_V	1×10^8 [16]
c_T	7.8×10^{-7} [16]
c_M	Fitted
c_G	Fitted
c	2.4 [16]
δ_T	0.1 [16]
r_T	0.281 [16]
K_T	3.16×10^4 [16]
r_B	Fitted
τ_b	Fitted
r_M	Fitted
q	Fitted
δ_M	0.0693 [23]
r_q	Fitted
K_q	Fitted
r_G	Fitted
δ_G	0.0277 [23]

163 that Model 6 had a better score for non-severe patients, but was not the best for severe patients. However, the difference
 164 between the score of Model 6 in non-severe with the rest of the models is greater than comparing Model 4 to 6 in the
 165 severe patient group, therefore we chose Model 6 as the one that best explains the viral dynamic and immune response.
 166 The AIC scores can be consulted in the Supplementary Material.

167 Figure 6 display the dynamics of the viral load and the immune response for one severe patient from group D
 168 (severe D), one severe patient from group E (severe E), and one non-severe patient from group F and G, using Model
 169 6. In Figure 6e we can observe the fit of the IgG response of Model 6 with the experimental data points. In these
 170 particular cases, the peak of the viral load for the severe E patient in Figure 6a was lower than other two, while severe
 171 D patient took more days to clear the virus. The peak of T cell level for the severe D patient in Figure 6b was higher
 172 than other two cases, and severe E patient had the lowest T cell response in accordance with her/his lower viral load.
 173 The B cell level for severe D patient in Figure 6c maintained a higher level until the end of the disease, while the severe
 174 E had the lowest level again. The non-severe patient had the highest IgM antibody level in Figure 6d and severe D
 175 patient had the lowest IgG antibody level in Figure 6e.

176 A total of 9 parameters were optimized in Model 6 and each patient had a set of parameters that best fit their antibody
 177 IgG response data. The distribution of each parameter for all patients can be consulted in the Supplementary Material.
 178 The parameters r_B , r_M and r_G presented little variation between patients, even between severe and non-severe patients;
 179 these parameters represent the proliferation of B cells, antibodies IgM and antibodies IgG, respectively. This result
 180 suggests that the B cell response and the antibody IgM level do not play an important role in identifying a severe patient.




Figure 6: Numerical results of the Model 6 using antibody IgG level data from one severe patient from group D, one severe patient from group E, and non-severe patient. (a) Viral load level, (b) T cell level, (c) B cell level, (d) antibody IgM level and (e) antibody IgG level. The points in (e) are experimental data of antibody IgG level reported in [21], triangle for severe D case (Patient ID: 5), circle for a severe E case (Patient ID: 3) and square for a non-severe case (Patient ID: 1). Notice the log base 10 scale in (a) and (c), and log base 2 scale in (d) and (e).

181 Although r_G does not vary sufficiently between two groups of patients, q show a difference where the non-severe group
 182 has lower values, while severe group has uniformly distributed values. The rest of the parameters do not show clear
 183 differences between groups, tending to a uniform distribution in both groups. It should be noticed that the group of
 184 severe patients is not large enough to give conclusive results.

185 In Table 2 is displayed the median of the estimated parameters of the patients in the non-severe group and the two
 186 severe groups. The parameters that varied the most in their medians were c_G , r_M , and r_G , with orders of magnitude
 187 among patient groups. It can be noticed that r_q and r_G values are lower in non-severe patients than severe D patients,
 188 however these patients have a viral load clearance similar to severe D patients; this suggests that severe D patients
 189 do not produce "quality" antibodies that help to viral shedding, which consequently leads to more severe symptoms.
 190 We can also note that although severe D patients have generally better parameters than severe E patients they have a
 191 early B-cell proliferation (low values of τ_B); this result support the idea of quality antibody production, having early
 192 antibody production lowers the efficiency in clearing viral load.

Table 2

Median of the optimized parameters of severe D patients, severe E patients and non-severe patients.

Parameter	Non-severe	Severe D	Severe E
c_M	5.78×10^{-3}	6.06×10^{-3}	2.74×10^{-3}
c_G	0.148	0.281	0.026
r_B	0.145	0.233	0.205
τ_B	18.5	2.95	36.1
r_M	6.78×10^{-7}	1.92×10^{-4}	1.5×10^{-6}
q	0.0285	0.0732	0.0012
r_q	0.564	7.76	0.165
K_q	326	23.5	378
r_G	9.05×10^{-8}	4.77×10^{-4}	1.0×10^{-9}

193 3. Discussion

194 In this work, we used the mapper algorithm for the exploration of antibody level data of patients with COVID-19.
195 Using this tool, we identified three groups of patients: non-severe, severe and a group with intermediate severity. We
196 found that the last two groups have a notable difference in the level of IgG antibodies, being higher in the intermediate
197 group.

198 On the other hand, we set out to model the immune system response against SARS-CoV-2 viral infection by focusing
199 on the antibody response. It is not yet clear how the immune system of a patient presenting with severe symptoms
200 fails to clear the viral load from the body, however, it has been reported that severe COVID-19 patients have high IgG
201 antibody levels [45, 21]. Therefore, we proposed six mathematical models that represent the response of the immune
202 system against viral infection; we estimated the parameters related to B cell response and IgM and IgG antibodies
203 using IgG antibody data reported COVID-19 patients. Among all models, Model 6 provided the best fit to the IgG
204 data. Our results show that the key parameters between the dynamics of severe and non-severe patients are those related
205 to antibody proliferation and viral clearance by IgG antibody.

206 In Table 2 we can observe that the severe D patients have a early B cell proliferation, this confers an early response
207 by B cells, which in turn trigger the production of antibodies. This early B cell production in severe patients leads
208 to a rapid proliferation of antibodies, as we can see from the higher values of r_M and r_G in the severe D group. Due
209 to this short response time, the antibodies produced by these severe patients could not have enough time to carry out
210 the selection process of the optimal receptor for binding with the S protein of the virus, and therefore they would be
211 considered of low quality or even not having neutralizing capacity. This could be the reason why they do not have a
212 great contribution in viral clearance, since the parameter c_G corresponding to viral clearance by IgG antibody is lower
213 in severe patients. This suggest that antibodies produced by severe patients do not present the expected neutralizing
214 response, considered of low quality as reported by Vanshylla et al. [48]. Different works have identified antibodies

215 that potentially can neutralize SARS-CoV-2 derived from individuals infected with COVID-19 [18, 19, 36]. In fact,
216 there is evidence that robust neutralizing antibodies to SARS-CoV-2 infection could persist for several months [25].
217 Furthermore, cross-reactivity in antibody binding to the spike protein is common, but cross-neutralization of the live
218 viruses is rare[22]. Nevertheless, antibody affinity may have several implications. In fact, limited antibody protection
219 against any virus have a theoretical potential to amplify the infection [3].

220 Another key process in differentiating severe and non-severe patients is the ancillary process in IgG production
221 by the seroconversion period. This process proved to be key to emulate the SARS-CoV-2 infection process and the
222 adaptive immune response, since considering a sigmoidal activation function of the seroconversion process from IgM
223 to IgG improved the score of the Model 6. The rate of antibody IgM converted to IgG due to the seroconversion
224 process, represented by q , was higher in severe D patients, which implies that there is a delay in the seroconversion
225 process in non-severe patients. The latter suggests that in non-severe patients there persists a level of IgM antibodies
226 that help in viral clearance before activating the seroconversion process; in severe patients there is an early production
227 of IgG antibodies that are not efficient in neutralizing viral particles.

228 Since model 6 was the best fit to the data, we performed a stability analysis. This analysis can help us understand
229 how the immune system, and especially the antibodies, clear the viral load. If we take $m = 2$ then we can expect up to
230 5 equilibrium points in the 5-dimensional Model 6, and the existence criteria of each type of equilibrium is studied. A
231 point of stability is when there are no viral particles, and it is asymptotically stable. There is at least a virus-positive
232 equilibrium point, $\lambda > 0$, this means that the viral proliferation rate p is not overwhelmed by the elimination rates c
233 and c_T .

234 4. Methodologies

235 4.1. Experimental data details

236 In this work we used experimental data reported by Long *et al.* [21]. In that study the authors reported the antibody
237 response of 285 COVID-19 patients of which 70 had sequential samples available. The patients were enrolled from
238 three hospitals in Chongqing, a municipality adjacent to Hubei province. The median age of the patients was 47 years
239 and 54.5% were males. Serological samples were collected from symptoms onset and the detection of IgM and IgG
240 levels in response to SARS-Cov-2 was carried out using MCLIA (Magnetic Chemiluminescence Immunoassay) kits.
241 The antibody levels were presented as the measured chemiluminescence values divided by the cutoff value which was
242 defined by receiver operating characteristic curves.

243 Of the 285 patients, 39 were classified as severe or in critical condition and 63 patients were followed up for
244 serological sampling, where samples were taken at 3-day intervals between February 8, 2020 and the patient's discharge
245 from the hospital. Of the latter group, 100% tested positive for the presence of IgG antibody approximately 17-19 days

Table 3

Parameters used in mapper algorithm for each data set.

Parameter	262-patients dataset	41-patients dataset
Metric space	cosine	cosine
Lens	Eccentricity (exp = 2)	Eccentricity (exp = 2)
Clustering algorithm	DBSCAN (eps = 0.01)	DBSCAN (eps = 0.1)
Number of intervals	100	100
Percentage overlap	95%	88%

246 after the symptoms onset (daso), while 94% of the patients reached peak IgM levels approximately 20-22 daso. IgG
247 and IgM levels in the group of patients classified as severe were higher than the non-severe group, however a significant
248 difference was only observed in IgG levels. More details can be found in the original paper [21].

249 **4.2. Mapper algorithm**

250 For the topological analysis of the data, the *giotto-tda* package was used [46]. This package integrates various
251 TDA tools with machine learning using an API compatible with scikit-learn and C++ implementations. This package
252 has the great advantage of providing a balance between interoperability and computational efficiency, which is useful
253 given the sensitivity of the mapper to parameter changes. The latter is still an important problem, as there is still no
254 clear methodology for parameter selection. In [6, 44] the authors explore ways to attack this problem using category
255 theory.

256 As mentioned above, the choice of parameters of the mapper algorithm directly influences the results obtained.
257 Among the parameters that can be modified are the metric space, lens, clustering algorithm, number of intervals
258 and percentage overlap. In a previous work, Sasaki et al. [40] studied with TDA the shape of the immune response
259 during co-infections, in this work the mapper algorithm and each of the listed parameters are described in detail; it is
260 recommended to refer to that work to obtain a broader overview of this analysis tool.

261 In Table 3 is displayed the parameters used for the analysis of the two data sets, considering a sample per patient
262 for 262 patients, and longitudinal samples of 41 patients. It should be pointed out that we tested different choices of
263 parameters, but we only present the ones with which we obtained the best results for this data set.

264 **4.3. Parameter estimation**

Mathematical models proposed in this work is based on Ordinary Differential Equations (ODEs). The ODEs were solved using the PDEparams module [31], which integrates the differential equations using SciPy's odeint. We used different mechanistic modeling strategies, a total of 6 models were tested. The estimation of the free parameters was performed using the same PDEparams module where the parameter estimation is carried out using Differential Evolution (DE) algorithm [43], which minimize a cost function. In this work we used experimental data that are given

in logarithmic scale, therefore we use the Root Mean Square Log Error (RMSLE) as cost function and is given by:

$$\text{RMSLE} = \sqrt{\frac{1}{n} \sum_{i=1}^n (\log(y_i) - \log(\bar{y}_i))^2}, \quad (23)$$

265 where n is the number of data points (samples), y_i is the experimental measure of the i -th sample and \bar{y}_i is the predictive
266 output of the model.

267 As several models can provide the same fit with observed experimental data, it becomes necessary to choose
268 between different models. The standard approach to model selection is first estimate all model parameters from the
269 data, then select the model with the best-fit error and some penalties on model complexity. In this work we used the
270 next model selection criteria.

Definition 1. Akaike Information Criterion (AIC). The corrected (AIC) writes as follows:

$$\text{AIC} = n \log\left(\frac{\text{RSS}}{n}\right) + \frac{2mn}{n - m - 1} \quad (24)$$

271 where n is the number of data points, m is the unknown parameters and RSS is the residual sum of squares obtained
272 from the fitting routine. The lowest AIC value of a given model, the best description of the data better respect the other
273 models. Small differences in AIC scores (*e.g.* <2) are not significant [7].

274 Conflict of Interest

275 The author declares that the research was conducted in the absence of any commercial or financial relationships
276 that could be construed as a potential conflict of interest.

277 Acknowledgment

278 This research was funded by the Universidad Nacional Autonoma de México (UNAM) and the Alfons und Gertrud
279 Kassel-Stiftung.

280 References

- 281 [1] Abuin, P., Anderson, A., Ferramosca, A., Hernandez-vargas, E.A., Gonzalez, A.H., 2020. Annual Reviews in Control Characterization
282 of SARS-CoV-2 dynamics in the host. Annual Reviews in Control URL: <https://doi.org/10.1016/j.arcontrol.2020.09.008>,
283 doi:10.1016/j.arcontrol.2020.09.008.
- 284 [2] Almocera, A.E.S., Quiroz, G., Hernandez-Vargas, E.A., 2020. Stability analysis in COVID-19 within-host model with immune response.
285 Communications in Nonlinear Science and Numerical Simulation doi:10.1016/j.cnsns.2020.105584.

- 286 [3] Arvin, A.M., Fink, K., Schmid, M.A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., Virgin, H.W., 2020. A
287 perspective on potential antibody-dependent enhancement of SARS-CoV-2. *Nature* 584, 353–363. URL: <http://dx.doi.org/10.1038/s41586-020-2538-8>, doi:10.1038/s41586-020-2538-8.
- 289 [4] Baccam, P., Beauchemin, C., Macken, C.a., Hayden, F.G., Perelson, A.S., 2006. Kinetics of influenza A virus infection in humans. *Journal of virology* 80, 7590–9. URL: <http://www.ncbi.nlm.nih.gov/pubmed/16840338>, doi:10.1128/JVI.01623-05.
- 290 [5] Blanco-Rodríguez, R., Du, X., Hernández-Vargas, E., 2021. Computational simulations to dissect the cell immune response dynamics for
291 severe and critical cases of sars-cov-2 infection. *Computer methods and programs in biomedicine* 211, 106412.
- 292 [6] Bui, Q.T., Vo, B., Do, H.A.N., Hung, N.Q.V., Snasel, V., 2020. F-mapper: A fuzzy mapper clustering algorithm. *Knowledge-Based Systems*
293 189, 105107.
- 294 [7] Burnham, K.P., Anderson, D.R., 2002. *Model selection and multimodel inference: a practical information-theoretic approach*. Springer
295 Science & Business Media.
- 296 [8] Dobrovolny, H.M., Reddy, M.B., Kamal, M.a., Rayner, C.R., Beauchemin, C.a.a., 2013. Assessing Mathematical Models of Influenza Infec-
297 tions Using Features of the Immune Response. *PLoS ONE* 8, e57088.
- 298 [9] Du, S.Q., Yuan, W., 2020. Mathematical Modeling of Interaction between Innate and Adaptive Immune Responses in COVID-19 and Impli-
299 cations for Viral Pathogenesis. *Journal of Medical Virology* , 0–2doi:10.1002/jmv.25866.
- 300 [10] Ejima, K., Kim, K.S., Ito, Y., Iwanami, S., Ohashi, H., Koizumi, Y., Watashi, K., Bento, A.I., Aihara, K., Iwami, S., 2020. Inferring
301 Timing of Infection Using Within-host SARS-CoV-2 Infection Dynamics Model: Are "Imported Cases" Truly Imported? medRxiv 4297,
302 2020.03.30.20040519. doi:10.1101/2020.03.30.20040519.
- 303 [11] Gonçalves, A., Bertrand, J., Ke, R., Comets, E., de Lamballerie, X., Malvy, D., Pizzorno, A., Terrier, O., Calatrava, M.R., Mentré, F.,
304 Smith, P., Perelson, A.S., Guedj, J., 2020. Timing of antiviral treatment initiation is critical to reduce SARS-Cov-2 viral load. medRxiv
305 URL: <http://www.ncbi.nlm.nih.gov/pubmed/32511641>[http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7276997)
306 [PMC7276997](http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7276997), doi:10.1101/2020.04.04.20047886.
- 307 [12] Goyal, A., Cardozo-Ojeda, E., Schiffer, J.T., 2020. Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2
308 shedding and intensity of inflammatory response. medRxiv , 2020.04.10.20061325URL: [http://medrxiv.org/content/early/2020/](http://medrxiv.org/content/early/2020/04/14/2020.04.10.20061325.abstract)
309 [http://medrxiv.org/content/early/2020/](http://medrxiv.org/content/early/2020/04/14/2020.04.10.20061325.abstract)
310 [04/14/2020.04.10.20061325.abstract](http://medrxiv.org/content/early/2020/04/14/2020.04.10.20061325.abstract), doi:10.1101/2020.04.10.20061325.
- 311 [13] Graw, F., Perelson, A.S., 2015. Modeling Viral Spread. *Annual Review of Virology* , 1–18URL: [http://www.annualreviews.org/doi/](http://www.annualreviews.org/doi/abs/10.1146/annurev-virology-110615-042249)
312 [abs/10.1146/annurev-virology-110615-042249](http://www.annualreviews.org/doi/abs/10.1146/annurev-virology-110615-042249), doi:10.1146/annurev-virology-110615-042249.
- 313 [14] Hernandez-Vargas, A.E., Meyer-Hermann, M., 2012. Innate immune system dynamics to influenza virus. *IFAC Proceedings Volumes* 45,
314 260–265.
- 315 [15] Hernandez-Vargas, E., 2017. Modeling kick-kill strategies toward HIV cure. *Frontiers in Immunology* 8. doi:10.3389/fimmu.2017.00995.
- 316 [16] Hernandez-Vargas, E.A., Velasco-Hernandez, J.X., 2020. In-host Mathematical Modelling of COVID-19 in Humans. *Annual Reviews in*
317 *Control* doi:10.1016/j.arcontrol.2020.09.006.
- 318 [17] Hernandez-Vargas, E.A., Wilk, E., Canini, L., Toapanta, F.R., Binder, S.C., Uvarovskii, A., Ross, T.M., Guzman, C., Perelson, A.S., Meyer-
319 Hermann, M., 2014. Effects of aging on influenza virus infection dynamics. *Journal of Virology* 88, 4123–31.
- 320 [18] Ju, B., Zhang, Q., Ge, J., Wang, R., Sun, J., Ge, X., Yu, J., Shan, S., Zhou, B., Song, S., Tang, X., Yu, J., Lan, J., Yuan, J., Wang, H., Zhao, J.,
321 Zhang, S., Wang, Y., Shi, X., Liu, L., Zhao, J., Wang, X., Zhang, Z., Zhang, L., 2020. Human neutralizing antibodies elicited by SARS-CoV-2
322 infection. *Nature* 584, 115–119. URL: <http://dx.doi.org/10.1038/s41586-020-2380-z>, doi:10.1038/s41586-020-2380-z.
- 323 [19] Liu, L., Wang, P., Nair, M.S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J.F., Sahi, V., Figueroa, A., Guo, X.V., Cerutti, G., Bimela, J.,

- 324 Gorman, J., Zhou, T., Chen, Z., Yuen, K.Y., Kwong, P.D., Sodroski, J.G., Yin, M.T., Sheng, Z., Huang, Y., Shapiro, L., Ho, D.D., 2020.
325 Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature* 584, 450–456. URL: [http://dx.doi.org/10.](http://dx.doi.org/10.1038/s41586-020-2571-7)
326 [1038/s41586-020-2571-7](http://dx.doi.org/10.1038/s41586-020-2571-7), doi:10.1038/s41586-020-2571-7.
- 327 [20] Liu, Y., Yan, L.M., Wan, L., Xiang, T.X., Le, A., Liu, J.M., Peiris, M., Poon, L.L.M., Zhang, W., . Viral dynamics in mild and se-
328 vere cases of COVID-19. *The Lancet Infectious Diseases* 0. URL: [https://www.thelancet.com/journals/laninf/article/](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30232-2/fulltext)
329 [PIIS1473-3099\(20\)30232-2/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30232-2/fulltext), doi:10.1016/S1473-3099(20)30232-2.
- 330 [21] Long, Q.X., Liu, B.Z., Deng, H.J., Wu, G.C., Deng, K., Chen, Y.K., Liao, P., Qiu, J.F., Lin, Y., Cai, X.F., et al., 2020. Antibody responses to
331 sars-cov-2 in patients with covid-19. *Nature Medicine* 26, 845–848.
- 332 [22] Lv, H., Wu, N.C., Tsang, O.T.Y., Yuan, M., Perera, R.A.P.M., Leung, W.S., So, R.T.Y., Chan, J.M.C., Yip, G.K., Chik, T.S.H., Wang, Y.,
333 Choi, C.Y.C., Lin, Y., Ng, W.W., Zhao, J., Poon, L.L.M., Peiris, J.S.M., Wilson, I.A., Mok, C.K.P., 2020. Cross-reactive antibody response
334 between SARS-CoV-2 and SARS-CoV infections. *bioRxiv* , 2020.03.15.993097URL: [https://www.biorxiv.org/content/10.1101/](https://www.biorxiv.org/content/10.1101/2020.03.15.993097v1)
335 [2020.03.15.993097v1](https://www.biorxiv.org/content/10.1101/2020.03.15.993097v1), doi:10.1101/2020.03.15.993097.
- 336 [23] Mankarious, S., Lee, M., Fischer, S., Pyun, K., Ochs, H., Oxelius, V., Wedgwood, R., 1988. The half-lives of igg subclasses and specific anti-
337 bodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin. *The Journal of Laboratory*
338 *and Clinical Medicine* 112, 634–640.
- 339 [24] Miao, H., Hollenbaugh, J.A., Zand, M.S., Holden-Wiltse, J., Mosmann, T.R., Perelson, A.S., Wu, H., Topham, D.J., 2010. Quantifying
340 the Early Immune Response and Adaptive Immune Response Kinetics in Mice Infected with Influenza A Virus. *Journal of Virology* 84,
341 6687–6698. URL: <http://jvi.asm.org/cgi/doi/10.1128/JVI.00266-10>, doi:10.1128/JVI.00266-10.
- 342 [25] Mudd, P.A., Adv, S., Mudd, P.A., Crawford, J.C., Turner, J.S., Souquette, A., Reynolds, D., Bosanquet, J.P., Anand, N.J., Striker, D.A., Martin,
343 R.S., Boon, A.C.M., House, S.L., Remy, K.E., Hotchkiss, R.S., Presti, R.M., Halloran, J.A.O., Powderly, W.G., Thomas, P.G., Ellebedy, A.H.,
344 2020. Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine storm. *Science* 3024,
345 1–21. doi:10.1126/sciadv.abe3024.
- 346 [26] Nguyen, V.K., Binder, S.C., Boianelli, A., Meyer-Hermann, M., Hernandez-Vargas, E.A., 2015. Ebola virus infection modeling and identifi-
347 ability problems. *Frontiers in Microbiology* 6, 1–11.
- 348 [27] Nguyen, V.K., Hernandez-Vargas, E.A., 2017. Windows of opportunity for Ebola virus infection treatment and vaccination. *Scientific reports*
349 7, 8975.
- 350 [28] Nicolau, M., Levine, A.J., Carlsson, G., 2011. Topology based data analysis identifies a subgroup of breast cancers with a unique mutational
351 profile and excellent survival. *Proceedings of the National Academy of Sciences* 108, 7265–7270.
- 352 [29] Oh, M.d., Park, W.B., Choe, P.G., Choi, S.J., Kim, J.I., Chae, J., Park, S.S., Kim, E.C., Oh, H.S., Kim, E.J., Nam, E.Y., Na, S.H., Kim,
353 D.K., Lee, S.M., Song, K.H., Bang, J.H., Kim, E.S., Kim, H.B., Park, S.W., Kim, N.J., 2016. Viral Load Kinetics of MERS Coronavirus
354 Infection. *New England Journal of Medicine* 375, 1303–1305. URL: <http://www.nejm.org/doi/10.1056/NEJMc1511695>, doi:10.
355 [1056/NEJMc1511695](http://www.nejm.org/doi/10.1056/NEJMc1511695).
- 356 [30] Oja, A.E., Saris, A., Ghandour, C.A., Kragten, N.A., Hogema, B.M., Nossent, E.J., Heunks, L.M., Cuvalay, S., Slot, E., Linty, F., Swaneveld,
357 F.H., Vrieling, H., Vidarsson, G., Rispens, T., Schoot, E., Lier, R.A., Brinke, A.T., Hombrink, P., 2020. Divergent SARS-CoV-2-specific T
358 and B cell responses in severe but not mild COVID-19 patients. *European Journal of Immunology* doi:10.1002/eji.202048908.
- 359 [31] Parra-Rojas, C., Hernandez-Vargas, E.A., 2020. Pdeparams: Parameter fitting toolbox for partial differential equations in python. *Bioinform-*
360 *atics* 36, 2618–2619.
- 361 [32] Pawelek, K.A., Huynh, G.T., Quinlivan, M., Cullinane, A., Rong, L., Perelson, A.S., 2012. Modeling Within-Host Dynamics of Influenza

- 362 Virus Infection Including Immune Responses. *PLoS Comput Biol* 8, e1002588.
- 363 [33] Peiris, J.S.M., Chu, C.M., Cheng, V.C.C., Chan, K.S., Hung, I.F.N., Poon, L.L.M., Law, K.I., Tang, B.S.F., Hon, T.Y.W., Chan, C.S., Chan,
364 K.H., Ng, J.S.C., Zheng, B.J., Ng, W.L., Lai, R.W.M., Guan, Y., Yuen, K.Y., HKU/UCH SARS Study Group, 2003. Clinical progression
365 and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. *Lancet* (London, England) 361,
366 1767–72. URL: <http://www.ncbi.nlm.nih.gov/pubmed/12781535>, doi:10.1016/s0140-6736(03)13412-5.
- 367 [34] Perelson, A.S., Ribeiro, R.M., 2013. Modeling the within-host dynamics of HIV infection. *BMC Biology* 11, 96. URL: <http://bmcbiol.biomedcentral.com/articles/10.1186/1741-7007-11-96>, doi:10.1186/1741-7007-11-96, arXiv:9903017.
- 368
369 [35] Pinkevych, M., Kent, S.J., Tolstrup, M., Lewin, S.R., Cooper, D.A., Sogaard, O.S., Rasmussen, T.A., Kelleher, A.D., Cromer, D., Davenport,
370 M.P., 2016. Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every
371 5–8 Days. *PLoS Pathogens* 12, 8–11. URL: <http://dx.doi.org/10.1371/journal.ppat.1005740>, doi:10.1371/journal.ppat.1005740.
372
- 373 [36] Ravichandran, S., Coyle, E.M., Klenow, L., Tang, J., Grubbs, G., Liu, S., Wang, T., Golding, H., Khurana, S., 2020. Antibody signature induced
374 by SARS-CoV-2 spike protein immunogens in rabbits. *Science Translational Medicine* 12, 1–9. doi:10.1126/SCITRANSLMED.ABC3539.
- 375 [37] Reluga, T.C., Dahari, H., Perelson, A.S., 2009. Analysis of Hepatitis C Virus Infection Models with Hepatocyte Homeostasis. *SIAM journal*
376 *on applied mathematics* 69, 999–1023.
- 377 [38] Robles, A., Hajj, M., Rosen, P., 2017. The shape of an image: A study of mapper on images. arXiv preprint arXiv:1710.09008 .
- 378 [39] Rong, L., Ā, A.S.P., 2009. Modeling HIV persistence , the latent reservoir , and viral blips. *Journal of Theoretical Biology* 260, 308–331.
379 URL: <http://dx.doi.org/10.1016/j.jtbi.2009.06.011>, doi:10.1016/j.jtbi.2009.06.011.
- 380 [40] Sasaki, K., Bruder, D., Hernandez-Vargas, E.A., 2020. Topological data analysis to model the shape of immune responses during co-infections.
381 *Communications in Nonlinear Science and Numerical Simulation* 85, 105228.
- 382 [41] Singh, G., Mémoli, F., Carlsson, G.E., et al., 2007. Topological methods for the analysis of high dimensional data sets and 3d object recognition.
383 *Eurographics Symposium on Point-Based Graphics* 2.
- 384 [42] Smith, A.M., Adler, F.R., McAuley, J.L., Gutenkunst, R.N., Ribeiro, R.M., McCullers, J.A., Perelson, A.S., 2011. Effect of 1918 PB1-F2
385 expression on influenza A virus infection kinetics. *PLoS computational biology* 7, e1001081. doi:10.1371/journal.pcbi.1001081.
- 386 [43] Storn, R., Price, K., 1997. Differential evolution—a simple and efficient heuristic for global optimization over continuous spaces. *Journal of*
387 *global optimization* , 341–359doi:10.1023/A:1008202821328.
- 388 [44] Stovner, R.B., 2012. On the mapper algorithm: A study of a new topological method for data analysis. Master's thesis. Institutt for Matematiske
389 Fag.
- 390 [45] Tan, W., Lu, Y., Zhang, J., Wang, J., Dan, Y., Tan, Z., He, X., Qian, C., Sun, Q., Hu, Q., Liu, H., Ye, S., Xiang, X., Zhou, Y., Zhang, W.,
391 Guo, Y., Wang, X.H., He, W., Wan, X., Sun, F., Wei, Q., Chen, C., Pan, G., Xia, J., Mao, Q., Chen, Y., Deng, G., 2020. Viral Kinetics and
392 Antibody Responses in Patients with COVID-19. medRxiv , 2020.03.24.20042382URL: <http://medrxiv.org/content/early/2020/03/26/2020.03.24.20042382.abstract>, doi:10.1101/2020.03.24.20042382.
393
- 394 [46] Tauzin, G., Lupo, U., Tunstall, L., Pérez, J.B., Caorsi, M., Medina-Mardones, A.M., Dassatti, A., Hess, K., 2021. giotto-tda: A topological
395 data analysis toolkit for machine learning and data exploration. *Journal of Machine Learning Research* 22, 39–1.
- 396 [47] Tay, M.Z., Poh, C.M., Rénia, L., MacAry, P.A., Ng, L.F., 2020. The trinity of COVID-19: immunity, inflammation and intervention. *Nature*
397 *Reviews Immunology* 20, 363–374. URL: <http://dx.doi.org/10.1038/s41577-020-0311-8>, doi:10.1038/s41577-020-0311-8.
- 398 [48] Vanshylla, K., Di Cristanziano, V., Kleipass, F., Dewald, F., Schommers, P., Gieselmann, L., Gruell, H., Schlotz, M., Ercanoglu, M.S., Stumpf,
399 R., et al., 2021. Kinetics and correlates of the neutralizing antibody response to sars-cov-2 infection in humans. *Cell Host & Microbe* 29,

400 917–929.

401 [49] Wölfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M.A., Niemeyer, D., Jones, T.C., Vollmar, P., Rothe, C.,
402 Hoelscher, M., Bleicker, T., Brünink, S., Schneider, J., Ehmann, R., Zwirgmaier, K., Drosten, C., Wendtner, C., 2020. Virological as-
403 sessment of hospitalized patients with COVID-2019. *Nature* , 1–10URL: <http://www.nature.com/articles/s41586-020-2196-x>,
404 doi:10.1038/s41586-020-2196-x.